CalciMedica, Inc. — Form SCHEDULE 13D
Filed July 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Bering Partners II GP, L.L.C. (San Francisco) filed a Schedule 13D on July 2, 2026, disclosing acquisition of beneficial ownership in CalciMedica, Inc. (La Jolla). The filing document itself does not contain the specific share count, percentage ownership, or dollar amount of the acquisition in the header metadata provided. The actual ownership details and transaction value must be in the exhibit documents (primary_doc.html/xml and EX-99.1.pdf), which are not reproduced in this text extract.
Why this rating
Schedule 13D is routine disclosure when crossing 5% threshold. Without specific ownership %, share count, or price, cannot assess materiality. Filing metadata alone insufficient to judge business impact.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.